| Primary |
| Drug Use For Unknown Indication |
66.7% |
| Hypertension |
11.7% |
| Drug Therapy |
4.0% |
| Cardiac Failure |
3.5% |
| Product Used For Unknown Indication |
3.2% |
| Diabetes Mellitus |
1.5% |
| Oedema Peripheral |
1.5% |
| Cardiac Failure Chronic |
1.2% |
| Localised Infection |
1.0% |
| Prostatitis |
1.0% |
| Abnormal Behaviour |
0.7% |
| Angina Pectoris |
0.7% |
| Atrial Fibrillation |
0.7% |
| Acute Pulmonary Oedema |
0.5% |
| Arteriogram Coronary |
0.5% |
| Essential Hypertension |
0.5% |
| Arrhythmia |
0.2% |
| Back Pain |
0.2% |
| Benign Prostatic Hyperplasia |
0.2% |
| Bronchopneumopathy |
0.2% |
|
| Renal Failure Acute |
15.2% |
| Vomiting |
13.0% |
| Orthostatic Hypotension |
6.5% |
| Pyrexia |
6.5% |
| Renal Failure |
6.5% |
| Respiratory Arrest |
6.5% |
| Urine Output Decreased |
6.5% |
| Localised Infection |
4.3% |
| Sepsis |
4.3% |
| Skin Discolouration |
4.3% |
| Urinary Retention |
4.3% |
| Weight Increased |
4.3% |
| Confusional State |
2.2% |
| Disturbance In Attention |
2.2% |
| Hypotension |
2.2% |
| Lichenoid Keratosis |
2.2% |
| Oesophageal Ulcer |
2.2% |
| Overdose |
2.2% |
| Pain |
2.2% |
| Palatal Oedema |
2.2% |
|
| Secondary |
| Drug Use For Unknown Indication |
54.2% |
| Hypertension |
15.3% |
| Drug Therapy |
5.6% |
| Cardiac Failure |
4.9% |
| Product Used For Unknown Indication |
2.4% |
| Glomerulonephritis Membranous |
2.1% |
| Oedema Peripheral |
2.1% |
| Cardiac Failure Chronic |
1.7% |
| Arrhythmia |
1.4% |
| Hypercholesterolaemia |
1.4% |
| Localised Infection |
1.4% |
| Myocardial Infarction |
1.4% |
| Prostatitis |
1.4% |
| Anxiety |
0.7% |
| Atrial Fibrillation |
0.7% |
| Cardiomyopathy |
0.7% |
| Cardiovascular Event Prophylaxis |
0.7% |
| Cerebral Infarction |
0.7% |
| Diabetes Mellitus |
0.7% |
| Diabetic Nephropathy |
0.7% |
|
| Renal Failure Acute |
21.2% |
| Vomiting |
15.4% |
| Pyrexia |
11.5% |
| Renal Failure |
7.7% |
| Respiratory Arrest |
5.8% |
| Localised Infection |
3.8% |
| Pulmonary Oedema |
3.8% |
| Squamous Cell Carcinoma |
3.8% |
| Transient Ischaemic Attack |
3.8% |
| Urinary Retention |
3.8% |
| Blood Creatine Phosphokinase Increased |
1.9% |
| Blood Creatinine Increased |
1.9% |
| Dyspnoea |
1.9% |
| Hypotension |
1.9% |
| Melaena |
1.9% |
| Oesophageal Ulcer |
1.9% |
| Oral Mucosal Erythema |
1.9% |
| Poisoning Deliberate |
1.9% |
| Tooth Fracture |
1.9% |
| Toxic Skin Eruption |
1.9% |
|
| Concomitant |
| Drug Use For Unknown Indication |
28.8% |
| Hypertension |
14.8% |
| Product Used For Unknown Indication |
13.1% |
| Asthma |
3.6% |
| Hiv Infection |
3.6% |
| Lung Adenocarcinoma Metastatic |
3.6% |
| Thrombosis Prophylaxis |
3.6% |
| Anaesthesia |
3.0% |
| Atrial Fibrillation |
2.7% |
| Bacteraemia |
2.4% |
| Candidiasis |
2.4% |
| Hypercholesterolaemia |
2.4% |
| Mantle Cell Lymphoma |
2.4% |
| Myocardial Infarction |
2.4% |
| Pain |
2.4% |
| Pain Management |
2.4% |
| Type 2 Diabetes Mellitus |
2.1% |
| Rheumatoid Arthritis |
1.8% |
| Depression |
1.5% |
| Osteoporosis |
1.5% |
|
| Anaemia Haemolytic Autoimmune |
6.9% |
| Rectal Haemorrhage |
6.9% |
| Sudden Death |
6.9% |
| Vascular Dementia |
6.9% |
| Hypokinesia |
5.2% |
| Neutropenia |
5.2% |
| Pyrexia |
5.2% |
| Sedation |
5.2% |
| Sensory Disturbance |
5.2% |
| Subileus |
5.2% |
| Toxic Skin Eruption |
5.2% |
| Transaminases Increased |
5.2% |
| Vertigo |
5.2% |
| Vomiting |
5.2% |
| Agranulocytosis |
3.4% |
| Deep Vein Thrombosis |
3.4% |
| Ejection Fraction Decreased |
3.4% |
| Pneumonia |
3.4% |
| Subcutaneous Haematoma |
3.4% |
| Superinfection Lung |
3.4% |
|
| Interacting |
| Hypertension |
27.3% |
| Lymphangitis |
18.2% |
| Hypertension Arterial |
13.6% |
| Cardiac Failure |
9.1% |
| Drug Use For Unknown Indication |
9.1% |
| Dyslipidaemia |
9.1% |
| Phlebitis |
9.1% |
| Type 2 Diabetes Mellitus |
4.5% |
|
| Pruritus |
50.0% |
| Lactic Acidosis |
25.0% |
| Renal Failure Acute |
25.0% |
|
